Skip to main content
INMB
NASDAQ Life Sciences

Shareholders to Vote on Highly Dilutive Equity Plan Amidst Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.36
Mkt Cap
$36.688M
52W Low
$1.09
52W High
$11.64
52W Position info
25% above low
Off High info
88% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

INMB sits 25% above its 52-week low of $1.09 on light trading volume (0.3× avg).

Summary

Inmune Bio, Inc. filed its definitive proxy statement, seeking shareholder approval for a new equity incentive plan that could significantly dilute existing shareholders, against a backdrop of a 'going concern' warning from its auditors.


Key Events · Corporate Governance and Compliance · INMB

  • Proposed Highly Dilutive Equity Plan

    Shareholders will vote on a plan to immediately increase authorized shares by 2,658,525 (10.0% of current outstanding) and include an evergreen provision for up to 10.0% annual increases for five years (2027-2031).

  • Ongoing 'Going Concern' Warning

    The company continues to operate under a 'substantial doubt about its ability to continue as a going concern,' as previously disclosed in its 10-K and noted in its former auditor's report.

  • Executive Compensation Details

    The filing reveals executive compensation, including modifications to stock options for the CEO, CFO, and CSO in November 2025, which involved reduced exercise prices.

  • Auditor Ratification

    Shareholders will ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2026, following the dismissal of Marcum LLP in May 2025.


Analysis · INMB · Life Sciences

Inmune Bio, Inc. is seeking shareholder approval for a Third Amended and Restated 2021 Stock Incentive Plan, which would immediately increase the shares authorized for issuance by 2,658,525 shares, representing 10.0% of current outstanding shares. This plan also includes an evergreen provision allowing for annual increases of up to 10.0% of outstanding shares for five years (2027-2031). This represents a substantial potential for future dilution for a nano-cap company already facing 'substantial doubt about its ability to continue as a going concern,' as noted in its recent 10-K and by its former auditor. While such plans are crucial for incentivizing employees, the magnitude of potential dilution is significant for a company in a precarious financial position. The filing also details executive compensation, including past option modifications with reduced exercise prices for key executives, which is a negative signal. Investors should carefully consider the long-term dilutive impact of this plan.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INMB was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.827 info
Change: -$0.348 (-30%) info
Market Cap: $25.603M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.827 info
Change: -$0.693 (-46%) info
Market Cap: $25.603M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.827 info
Change: -$0.583 (-41%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.827 info
Change: -$0.862 (-51%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.827 info
Change: -$0.803 (-49%) info
Market Cap: $25.603M info